Creating
Precision
Medicines

Who we are

We are a clinical stage biopharmaceutical research and development company with around 400 staff, including highly educated scientists and skilled technicians who share the same goal:

To create safe and effective precision medicines targeting intractable cancers and autoimmune diseases, improving the standard of care for patients.

Read more

What we do

We create precision medicines, based on patient-focused drug development, which bring innovative therapeutic solutions to patients with key unmet medical needs.

Our development programs are targeting specific intractable cancers and autoimmune diseases with the aim of creating innovative, safe and effective precision medicines, based on new biological entities: antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs).

Read more

Latest news

19 May 2023

Clinical Trials: Pathways to Progress
Read more

15 May 2023

U.S. Food and Drug Administration Issues Complete Response Letter for Byondis’ [Vic-]Trastuzumab Duocarmazine
Read more

17 April 2023

Preclinical Characterization of Anti-SIRPα mAb BYON4228 Published in Journal for ImmunoTherapy of Cancer
Read more

12 April 2023

Preclinical Data on the Potential of Byondis ADC BYON3521 Published in Molecular Cancer Therapeutics
Read more

17 January 2023

When Cancer Hits Close to Home
Read more

Our success and team spirit depends on the quality, dedication and personality of our people.

Are we a match?

We are open to business and research proposals that may be complementary to our portfolio and fit with our strategy.

Looking for synergy?

Our website uses cookies to improve your experience More information